24.02.2010
Covagen acquires Edmond de Rothschild Investment Partners
Covagen Ltd., an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomers), announced today the closing of a financing round with its existing shareholder Ventech and Edmond de Rothschild Investment Partners (EdRIP), who are joining as new investors.
Covagen Ltd. received the CTI Start-up Label in April 2008, and has today estimated 9 employees.
For more information go to http://www.covagen.com/